Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

for its Vyznova cell therapy to treat bullous keratopathy of the cornea, in March last year. In April 2022, Aurion Biotech raised $120m in a funding round from various biotech and ophthalmology ...

As Alcon Research seeks to block investee Aurion Biotech from listing on the New York Stock Exchange, another investor has come to Aurion’s defense. Deerfield Management has sued Alcon Research ...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies ...